Phase II Ipilimumab Monotherapy in Recurrent Platinum Sensitive Ovarian Cancer
What is the purpose of this trial?
-To assess the incidence of grade 3 or higher drug related adverse event in the study population during the induction period of ipilimumab (Day 1 of treatment to Week 24).
-To assess the best overall response rate (BORR) in the study population by mWHO, immune-related response criteria (irRC), and CA125 Rustin Criteria. [Rustin, GJ 1996; Gordon, JS 2003]
- 18 Years and older
- Bristol-Myers Squibb Company
- Last Updated:
- Study HIC#: